Please Wait.....
Report
Gout Market Research Report Forecast till 2030
Market Report I 2023-11-01 I 128 Pages I Market Research Future
Gout Market Research Report Forecast till 2030
Market Overview
Gout Market is anticipated to register a significant CAGR of 11.75% during the review period.
Gout is a kind of provocative joint pain that influences men beyond 40 a year old, have a high measure of uric corrosive in their blood. As per studies, its commonness and frequency have expanded over the most recent couple of many years. The rising commonness of gout because of changing way of life designs and the developing geriatric populace is supposed to help market development over the gauge period. For example, according to the article distributed by the Records of Rheumatic Sicknesses in June 2021, a cross country companion concentrates on utilizing information from the Clinical Practice Research Datalink, from 1997 to across the Coronavirus pandemic in 2021 saw that the predominance pace of gout has expanded from 0.98%in 1997 to 2.33% in 2021. Notwithstanding, as per a similar source, the frequency of gout expanded by 0.98/1,000 people in UK 2021. Thusly, the weight of gout is supposed to build the interest in drugs treating this condition, which is expected to impel the market development over the estimate period.
Market Segmentation
The Gout Market segmentation, based on treatment and diagnosis, includes diagnosis, treatment. The treatment segment is further sub segmented into NSAIDs, corticosteroids, colchicine, urate-lowering agents, and others.
The Gout Market segmentation is based on applications that include acute gout and chronic gout. The Gout Market segmentation is based on hospitals & clinics, specialty centers, and others.
Regional Insights
The North America region fragmented into US, and Canada. The North America region held the biggest market share in the Gout Endlessly market is represented USD 1.80 billion of every 2022 and is supposed to display a 12.03% CAGR during the review time frame. Further, in the North America region the US gout market represented the biggest market share. This is credited to the rising predominance of gout, developing reception of biologics, and rising Research and development exercises on regenerative prescriptions.
Europe gout market is supposed to represent the second-biggest market share because of the availability to cutting edge finding and treatment offices, the rising geriatric populace inclined to gout is driving up interest for powerful treatment and therapeutics and developing medical care consumption. The Asia-Pacific gout market is supposed to develop at a CAGR of 13.12% from 2023 to 2030. This is because of variables like further developing medical care framework, developing speculation by central parts with neighbourhood producers, and the rising patient populace experiencing gout.
The Rest of the World incorporates the Middle East, Africa, and Latin America. Middle East hold the significant market share in middle east and Africa region because of restricted medical care framework, a shortage of mindfulness regarding the side effects of the sickness, and an absence of talented experts to make gout therapeutics drugs are restricting the development of the gout market in Sub-Saharan Africa.
Major Players
Key Companies in the Gout Market are Novartis AG (Switzerland), Lannett (US), Horizon Therapeutics plc (US), Takeda Pharmaceutical Company Limited (Japan), GlaxoSmithKline plc (UK), Regeneron Pharmaceuticals, Inc (US), Teijin Limited (Japan), Viatris Inc (US), Boehringer Ingelheim International GmbH (Germany), and ROMEG Therapeutics, LLC (US).
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 13
1.1 OVERVIEW 13
2 MARKET INTRODUCTION 14
2.1 DEFINITION 14
2.2 SCOPE OF THE STUDY 14
2.3 RESEARCH OBJECTIVE 14
2.4 MARKET STRUCTURE 15
2.5 ASSUMPTIONS & LIMITATIONS 15
3 RESEARCH METHODOLOGY 16
3.1 DATA MINING 16
3.2 SECONDARY RESEARCH 17
3.3 PRIMARY RESEARCH 18
3.4 BREAKDOWN OF PRIMARY RESPONDENTS 19
3.5 FORECASTING TECHNIQUES 20
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21
3.6.1 BOTTOM-UP APPROACH 22
3.6.2 TOP-DOWN APPROACH 22
3.7 DATA TRIANGULATION 23
3.8 VALIDATION 23
4 MARKET DYNAMICS 24
4.1 OVERVIEW 24
4.2 DRIVERS 25
4.2.1 INCREASING PREVALENCE OF GOUT 25
4.2.2 RISING HEALTHCARE EXPENDITURE 25
4.2.3 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES 26
4.3 RESTRAINTS 27
4.3.1 SIDE EFFECTS OF GOUT THERAPEUTIC DRUGS 27
4.3.2 LACK OF AWARENESS AMONG PEOPLE 28
4.4 OPPORTUNITY 28
4.4.1 RISING NUMBER OF STRATEGIC INITIATIVES 28
5 MARKET FACTOR ANALYSIS 29
5.1 VALUE CHAIN ANALYSIS 29
5.1.1 R&D 30
5.1.2 MANUFACTURING 30
5.1.3 DISTRIBUTION & SALES 30
5.1.4 POST-SALES MONITORING 30
5.2 PORTER'S FIVE FORCES MODEL 31
5.2.1 THREAT OF NEW ENTRANTS 31
5.2.2 BARGAINING POWER OF SUPPLIERS 32
5.2.3 THREAT OF SUBSTITUTES 32
5.2.4 BARGAINING POWER OF BUYERS 32
5.2.5 INTENSITY OF RIVALRY 32
5.3 IMPACT OF COVID-19 ON THE GLOBAL GOUT MARKET 33
5.3.1 IMPACT ON VALUE CHAIN 33
5.3.2 IMPACT ON SUPPLY CHAIN 33
5.3.3 IMPACT ON KEY PLAYERS 33
6 GLOBAL GOUT MARKET, BY DIAGNOSIS & TREATMENT 34
6.1 OVERVIEW 34
6.2 DIAGNOSIS 36
6.3 TREATMENT 36
6.3.1 NSAIDS 37
6.3.2 CORTICOSTEROIDS 37
6.3.3 COLCHICINE 38
6.3.4 URATE-LOWERING AGENTS 38
6.3.5 OTHERS 39
7 GLOBAL GOUT MARKET, BY APPLICATION 40
7.1 OVERVIEW 40
7.2 ACUTE GOUT 41
7.3 CHRONIC GOUT 42
8 GLOBAL GOUT MARKET, BY END USER 43
8.1 OVERVIEW 43
8.2 HOSPITALS & CLINICS 44
8.3 SPECIALTY CENTERS 45
8.4 OTHERS 45
9 GLOBAL GOUT MARKET, BY REGION 46
9.1 OVERVIEW 46
9.2 NORTH AMERICA 48
9.2.1 US 50
9.2.2 CANADA 51
9.3 EUROPE 52
9.3.1 GERMANY 54
9.3.2 UK 55
9.3.3 FRANCE 56
9.3.4 ITALY 57
9.3.5 SPAIN 58
9.3.6 REST OF EUROPE 59
9.4 ASIA-PACIFIC 61
9.4.1 CHINA 63
9.4.2 JAPAN 64
9.4.3 INDIA 65
9.4.4 AUSTRALIA 66
9.4.5 SOUTH KOREA 67
9.4.6 REST OF ASIA PACIFIC 68
9.5 REST OF THE WORLD 69
9.5.1 MIDDLE EAST 71
9.5.2 AFRICA 72
9.5.3 LATIN AMERICA 73
10 COMPETITIVE LANDSCAPE 74
10.1 OVERVIEW 74
10.2 COMPETITIVE BENCHMARKING 75
10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL GOUT MARKET 76
10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL GOUT MARKET 77
10.5 KEY DEVELOPMENT ANALYSIS 77
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 78
10.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL 78
10.6.2 PARTNERSHIPS/ AGREEMENTS 78
10.7 FINANCIAL MATRIX 78
10.7.1 SALES (USD MILLION), 2022 78
10.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2022 79
11 COMPANY PROFILES 80
11.1 NOVARTIS AG 80
11.1.1 COMPANY OVERVIEW 80
11.1.2 FINANCIAL OVERVIEW 81
11.1.3 PRODUCTS OFFERED 81
11.1.4 KEY DEVELOPMENTS 81
11.1.5 SWOT ANALYSIS 82
11.1.6 KEY STRATEGIES 82
11.2 LANNETT 83
11.2.1 COMPANY OVERVIEW 83
11.2.2 FINANCIAL OVERVIEW 83
11.2.3 PRODUCTS OFFERED 84
11.2.4 KEY DEVELOPMENTS 84
11.2.5 KEY STRATEGIES 84
11.3 HORIZON THERAPEUTICS PLC 85
11.3.1 COMPANY OVERVIEW 85
11.3.2 FINANCIAL OVERVIEW 86
11.3.3 PRODUCTS OFFERED 86
11.3.4 KEY DEVELOPMENTS 86
11.3.5 KEY STRATEGIES 87
11.4 TAKEDA PHARMACEUTICAL COMPANY LIMITED 88
11.4.1 COMPANY OVERVIEW 88
11.4.2 FINANCIAL OVERVIEW 88
11.4.3 PRODUCTS OFFERED 89
11.4.4 KEY DEVELOPMENTS 89
11.4.5 KEY STRATEGIES 89
11.5 GLAXOSMITHKLINE PLC 90
11.5.1 COMPANY OVERVIEW 90
11.5.2 FINANCIAL OVERVIEW 91
11.5.3 PRODUCTS OFFERED 91
11.5.4 KEY DEVELOPMENTS 91
11.5.5 SWOT ANALYSIS 92
11.5.6 KEY STRATEGIES 92
11.6 REGENERON PHARMACEUTICALS, INC. 93
11.6.1 COMPANY OVERVIEW 93
11.6.2 FINANCIAL OVERVIEW 93
11.6.3 PRODUCTS OFFERED 94
11.6.4 KEY DEVELOPMENTS 94
11.6.5 KEY STRATEGIES 94
11.7 TEIJIN LIMITED 95
11.7.1 COMPANY OVERVIEW 95
11.7.2 FINANCIAL OVERVIEW 95
11.7.3 PRODUCTS OFFERED 96
11.7.4 KEY DEVELOPMENTS 96
11.7.5 SWOT ANALYSIS 96
11.7.6 KEY STRATEGIES 96
11.8 VIATRIS INC. 97
11.8.1 COMPANY OVERVIEWS 97
11.8.2 FINANCIAL OVERVIEW 98
11.8.3 PRODUCTS OFFERED 98
11.8.4 KEY DEVELOPMENTS 98
11.8.5 SWOT ANALYSIS 99
11.8.6 KEY STRATEGIES 99
11.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH. 100
11.9.1 COMPANY OVERVIEW 100
11.9.2 FINANCIAL OVERVIEW 101
11.9.3 PRODUCTS OFFERED 101
11.9.4 KEY DEVELOPMENTS 102
11.9.5 SWOT ANALYSIS 102
11.9.6 KEY STRATEGIES 102
11.10 ROMEG THERAPEUTICS, LLC 103
11.10.1 COMPANY OVERVIEW 103
11.10.2 FINANCIAL OVERVIEW 103
11.10.3 PRODUCTS OFFERED 103
11.10.4 KEY DEVELOPMENTS 103
11.10.5 KEY STRATEGIES 103
12 APPENDIX 104
12.1 REFERENCES 104
12.2 WORLD HEALTH ORGANIZATION 104
12.3 THE GOUT EDUCATION SOCIETY 104
12.4 ARTHRITIS FOUNDATION 104
12.5 AMERICAN ARTHRITIS SOCIETY 104
12.6 SOUTH AFRICAN RHEUMATISM AND ARTHRITIS ASSOCIATION (SARAA) 104
12.7 EMIRATES ARTHRITIS FOUNDATION 104
12.8 ARTHRITIS FOUNDATION OF ASIA 104
12.9 OSTEOARTHRITIS RESEARCH SOCIETY INTERNATIONAL (OARSI) 104
12.10 SOAR - SOCIETY FOR OSTEOARTHRITIS RESEARCH 104
12.11 THE EUROPEAN ALLIANCE OF ASSOCIATIONS FOR RHEUMATOLOGY 104
12.12 RELATED REPORTS 105
LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 15
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 18
TABLE 3 GLOBAL GOUT MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2030 (USD MILLION) 35
TABLE 4 GLOBAL GOUT MARKET, FOR DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION) 36
TABLE 5 GLOBAL GOUT MARKET, FOR TREATMENT, BY REGION, 2018-2030 (USD MILLION) 36
TABLE 6 GLOBAL GOUT MARKET, FOR NSAIDS, BY REGION, 2018-2030 (USD MILLION) 37
TABLE 7 GLOBAL GOUT MARKET, FOR CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION) 37
TABLE 8 GLOBAL GOUT MARKET, FOR COLCHICINE, BY REGION, 2018-2030 (USD MILLION) 38
TABLE 9 GLOBAL GOUT MARKET, FOR URATE-LOWERING AGENTS, BY REGION, 2018-2030 (USD MILLION) 38
TABLE 10 GLOBAL GOUT MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION) 39
TABLE 11 GLOBAL GOUT MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 41
TABLE 12 GLOBAL GOUT MARKET, FOR ACUTE GOUT, BY REGION, 2018-2030 (USD MILLION) 41
TABLE 13 GLOBAL GOUT MARKET, FOR CHRONIC GOUT, BY REGION, 2018-2030 (USD MILLION) 42
TABLE 14 GLOBAL GOUT MARKET, BY END USER, 2018-2030 (USD MILLION) 44
TABLE 15 GLOBAL GOUT MARKET, FOR HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION) 44
TABLE 16 GLOBAL GOUT MARKET, FOR SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION) 45
TABLE 17 GLOBAL GOUT MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION) 45
TABLE 18 GLOBAL: GOUT MARKET, BY REGION, 2018-2030 (USD MILLION) 46
TABLE 19 NORTH AMERICA: GOUT MARKET, BY COUNTRY, 2018-2030 (USD MILLION) 48
TABLE 20 NORTH AMERICA: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2018-2030 (USD MILLION) 49
TABLE 21 NORTH AMERICA: GOUT MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 49
TABLE 22 NORTH AMERICA: GOUT MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 49
TABLE 23 NORTH AMERICA: GOUT MARKET, BY END USER, 2018-2030 (USD MILLION) 49
TABLE 24 US: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2018-2030 (USD MILLION) 50
TABLE 25 US: GOUT MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 50
TABLE 26 US: GOUT MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 50
TABLE 27 US: GOUT MARKET, BY END USER, 2018-2030 (USD MILLION) 50
TABLE 28 CANADA: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2018-2030 (USD MILLION) 51
TABLE 29 CANADA: GOUT MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 51
TABLE 30 CANADA: GOUT MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 51
TABLE 31 CANADA: GOUT MARKET, BY END USER, 2018-2030 (USD MILLION) 51
TABLE 32 EUROPE: GOUT MARKET, BY COUNTRY, 2018-2030 (USD MILLION) 53
TABLE 33 EUROPE: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2018-2030 (USD MILLION) 53
TABLE 34 EUROPE: GOUT MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 53
TABLE 35 EUROPE: GOUT MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 54
TABLE 36 EUROPE: GOUT MARKET, BY END USER, 2018-2030 (USD MILLION) 54
TABLE 37 GERMANY: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2018-2030 (USD MILLION) 54
TABLE 38 GERMANY: GOUT MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 54
TABLE 39 GERMANY: GOUT MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 55
TABLE 40 GERMANY: GOUT MARKET, BY END USER, 2018-2030 (USD MILLION) 55
TABLE 41 UK: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2018-2030 (USD MILLION) 55
TABLE 42 UK: GOUT MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 55
TABLE 43 UK: GOUT MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 56
TABLE 44 UK: GOUT MARKET, BY END USER, 2018-2030 (USD MILLION) 56
TABLE 45 FRANCE: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2018-2030 (USD MILLION) 56
TABLE 46 FRANCE: GOUT MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 56
TABLE 47 FRANCE: GOUT MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 57
TABLE 48 FRANCE: GOUT MARKET, BY END USER, 2018-2030 (USD MILLION) 57
TABLE 49 ITALY: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2018-2030 (USD MILLION) 57
TABLE 50 ITALY: GOUT MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 57
TABLE 51 ITALY: GOUT MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 58
TABLE 52 ITALY: GOUT MARKET, BY END USER, 2018-2030 (USD MILLION) 58
TABLE 53 SPAIN: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2018-2030 (USD MILLION) 58
TABLE 54 SPAIN: GOUT MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 58
TABLE 55 SPAIN: GOUT MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 59
TABLE 56 SPAIN: GOUT MARKET, BY END USER, 2018-2030 (USD MILLION) 59
TABLE 57 REST OF EUROPE: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2018-2030 (USD MILLION) 59
TABLE 58 REST OF EUROPE: GOUT MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 59
TABLE 59 REST OF EUROPE: GOUT MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 60
TABLE 60 REST OF EUROPE: GOUT MARKET, BY END USER, 2018-2030 (USD MILLION) 60
TABLE 61 ASIA-PACIFIC: GOUT MARKET, BY COUNTRY, 2018-2030 (USD MILLION) 61
TABLE 62 ASIA-PACIFIC: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2018-2030 (USD MILLION) 62
TABLE 63 ASIA-PACIFIC: GOUT MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 62
TABLE 64 ASIA-PACIFIC: GOUT MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 62
TABLE 65 ASIA-PACIFIC: GOUT MARKET, BY END USER, 2018-2030 (USD MILLION) 62
TABLE 66 CHINA: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2018-2030 (USD MILLION) 63
TABLE 67 CHINA: GOUT MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 63
TABLE 68 CHINA: GOUT MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 63
TABLE 69 CHINA: GOUT MARKET, BY END USER, 2018-2030 (USD MILLION) 63
TABLE 70 JAPAN: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2018-2030 (USD MILLION) 64
TABLE 71 JAPAN: GOUT MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 64
TABLE 72 JAPAN: GOUT MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 64
TABLE 73 JAPAN: GOUT MARKET, BY END USER, 2018-2030 (USD MILLION) 64
TABLE 74 INDIA: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2018-2030 (USD MILLION) 65
TABLE 75 INDIA: GOUT MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 65
TABLE 76 INDIA: GOUT MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 65
TABLE 77 INDIA: GOUT MARKET, BY END USER, 2018-2030 (USD MILLION) 65
TABLE 78 AUSTRALIA: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2018-2030 (USD MILLION) 66
TABLE 79 AUSTRALIA: GOUT MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 66
TABLE 80 AUSTRALIA: GOUT MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 66
TABLE 81 AUSTRALIA: GOUT MARKET, BY END USER, 2018-2030 (USD MILLION) 66
TABLE 82 SOUTH KOREA: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2018-2030 (USD MILLION) 67
TABLE 83 SOUTH KOREA: GOUT MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 67
TABLE 84 SOUTH KOREA: GOUT MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 67
TABLE 85 SOUTH KOREA: GOUT MARKET, BY END USER, 2018-2030 (USD MILLION) 67
TABLE 86 REST OF ASIA PACIFIC: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2018-2030 (USD MILLION) 68
TABLE 87 REST OF ASIA PACIFIC: GOUT MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 68
TABLE 88 REST OF ASIA PACIFIC: GOUT MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 68
TABLE 89 REST OF ASIA PACIFIC: GOUT MARKET, BY END USER, 2018-2030 (USD MILLION) 68
TABLE 90 REST OF THE WORLD: GOUT MARKET, BY COUNTRY, 2018-2030 (USD MILLION) 69
TABLE 91 REST OF THE WORLD: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2018-2030 (USD MILLION) 70
TABLE 92 REST OF THE WORLD: GOUT MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 70
TABLE 93 REST OF THE WORLD: GOUT MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 70
TABLE 94 REST OF THE WORLD: GOUT MARKET, BY END USER, 2018-2030 (USD MILLION) 70
TABLE 95 MIDDLE EAST: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2018-2030 (USD MILLION) 71
TABLE 96 MIDDLE EAST: GOUT MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 71
TABLE 97 MIDDLE EAST: GOUT MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 71
TABLE 98 MIDDLE EAST: GOUT MARKET, BY END USER, 2018-2030 (USD MILLION) 71
TABLE 99 AFRICA: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2018-2030 (USD MILLION) 72
TABLE 100 AFRICA: GOUT MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 72
TABLE 101 AFRICA: GOUT MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 72
TABLE 102 AFRICA: GOUT MARKET, BY END USER, 2018-2030 (USD MILLION) 72
TABLE 103 LATIN AMERICA: GOUT MARKET, BY TREATMENT AND DIAGNOSIS, 2018-2030 (USD MILLION) 73
TABLE 104 LATIN AMERICA: GOUT MARKET, BY TREATMENT, 2018-2030 (USD MILLION) 73
TABLE 105 LATIN AMERICA: GOUT MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 73
TABLE 106 LATIN AMERICA: GOUT MARKET, BY END USER, 2018-2030 (USD MILLION) 73
TABLE 107 MAJOR PLAYERS IN THE GLOBAL GOUT MARKET 74
TABLE 108 MOST ACTIVE PLAYER IN THE GLOBAL GOUT MARKET 77
TABLE 109 PRODUCT LAUNCH/ PRODUCT APPROVAL 78
TABLE 110 PARTNERSHIPS/ AGREEMENTS 78
TABLE 111 NOVARTIS AG: PRODUCTS OFFERED 81
TABLE 112 LANNETT: PRODUCTS OFFERED 84
TABLE 113 HORIZON THERAPEUTICS PLC: PRODUCTS OFFERED 86
TABLE 114 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS OFFERED 89
TABLE 115 GLAXOSMITHKLINE PLC: PRODUCTS OFFERED 91
TABLE 116 REGENERON PHARMACEUTICALS, INC.: PRODUCTS OFFERED 94
TABLE 117 TEIJIN LIMITED: PRODUCTS OFFERED 96
TABLE 118 VIATRIS INC.: PRODUCTS OFFERED 98
TABLE 119 BOEHRINGER INGELHEIM INTERNATIONAL GMBH.: PRODUCTS OFFERED 101
TABLE 120 ROMEG THERAPEUTICS, LLC: PRODUCTS OFFERED 103
TABLE 121 ROMEG THERAPEUTICS, LLC: KEY DEVELOPMENTS 103
LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS 13
FIGURE 2 GLOBAL GOUT MARKET 15
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 21
FIGURE 4 MARKET DYNAMICS: GLOBAL GOUT MARKET 24
FIGURE 5 DRIVER IMPACT ANALYSIS 26
FIGURE 6 RESTRAINT IMPACT ANALYSIS 28
FIGURE 7 VALUE CHAIN: GLOBAL GOUT MARKET 29
FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL GOUT MARKET 31
FIGURE 9 GLOBAL GOUT MARKET SHARE, BY DIAGNOSIS AND TREATMENT, 2022 (%) 34
FIGURE 10 GLOBAL GOUT MARKET, BY DIAGNOSIS AND TREATMENT, 2022 (USD MILLION) 34
FIGURE 11 GLOBAL GOUT MARKET SHARE, BY TREATMENT, 2022 (%) 35
FIGURE 12 GLOBAL GOUT MARKET, BY TREATMENT, 2022 (USD MILLION) 35
FIGURE 13 GLOBAL GOUT MARKET SHARE, BY APPLICATION, 2022 (%) 40
FIGURE 14 GLOBAL GOUT MARKET, BY APPLICATION, 2022 (USD MILLION) 40
FIGURE 15 GLOBAL GOUT MARKET SHARE, BY END USER, 2022 (%) 43
FIGURE 16 GLOBAL GOUT MARKET, BY END USER, 2022 (USD MILLION) 43
FIGURE 17 GLOBAL: GOUT MARKET, BY REGION 2022 & 2030 (USD MILLION) 46
FIGURE 18 GLOBAL: GOUT MARKET SHARE, BY REGION 2022 (%) 47
FIGURE 19 NORTH AMERICA: GOUT MARKET, BY COUNTRY, 2022 (%) 48
FIGURE 20 EUROPE: GOUT MARKET SHARE, BY COUNTRY 2022 (%) 52
FIGURE 21 ASIA-PACIFIC: GOUT MARKET SHARE, BY COUNTRY, 2022 (%) 61
FIGURE 22 REST OF THE WORLD: GOUT MARKET SHARE, BY COUNTRY, 2022 (%) 69
FIGURE 23 BENCHMARKING OF MAJOR COMPETITORS 75
FIGURE 24 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL GOUT MARKET 76
FIGURE 25 GLOBAL GOUT MARKET: COMPETITIVE LANDSCAPE 77
FIGURE 26 SALES, 2022 78
FIGURE 27 RESEARCH & DEVELOPMENT EXPENDITURE, 2022 79
FIGURE 28 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 81
FIGURE 29 NOVARTIS AG: SWOT ANALYSIS 82
FIGURE 30 LANNETT: FINANCIAL OVERVIEW SNAPSHOT 83
FIGURE 31 HORIZON THERAPEUTICS PLC: FINANCIAL OVERVIEW SNAPSHOT 86
FIGURE 32 TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIAL OVERVIEW SNAPSHOT 88
FIGURE 33 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT 91
FIGURE 34 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 92
FIGURE 35 REGENERON PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT 93
FIGURE 36 TEIJIN LIMITED: FINANCIAL OVERVIEW SNAPSHOT 95
FIGURE 37 TEIJIN LIMITED: SWOT ANALYSIS 96
FIGURE 38 VIATRIS INC.: FINANCIAL OVERVIEW SNAPSHOT 98
FIGURE 39 VIATRIS INC: SWOT ANALYSIS 99
FIGURE 40 BOEHRINGER INGELHEIM INTERNATIONAL GMBH.: FINANCIAL OVERVIEW SNAPSHOT 101
FIGURE 41 BOEHRINGER INGELHEIM INTERNATIONAL GMBH.: SWOT ANALYSIS 102
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security